CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← MoonLake Immunotherapeutics (MLTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

MoonLake Immunotherapeutics (MLTX)

Pharmaceutical Preparations · market cap $1.1B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-01-04 (est.)
Phase 3
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
MoonLake Immunotherapeutics (MLTX) is a ~100-employee biotech with a ~$1.0B market cap whose lead asset, sonelokimab, is in Phase 3 for Hidradenitis Suppurativa. Our database shows a Phase 3 catalyst marked 'completed' on 2026-09-28, but the outcome is not in our data. The next calendar items are estimated Phase 3 events on 2027-01-04, flagged 9/10 importance.
The catalyst path
  • 2027-01-04 (est.)Phase 3 · Sonelokimabimp 9/10
Pipeline
AssetPhaseIndication
SonelokimabPhase 3Hidradenitis Suppurativa
RisankizumabPhase 3Arthritis, Psoriatic
Sonelokimab (M1095)Phase 2Hidradenitis Suppurativa
Price & technical context
3-month
-24.4%
6-month
-24.9%
12-month
-1.7%
52-wk range
$9.55–$22.16
vs 50-day MA
+4.4%
vs 200-day MA
-24.0%
Realized vol
71.0%
Max drawdown
-89.9%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for MLTX (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.